Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.

BMC medicine - 19 Sept 2023

Huang Hai, Liu Ao, Liang Yiming, Xin Yaqun, Liu Jiacheng, Hao Yining, Huang Da, Chen Lu, Li Wei, Jiang Guangliang, Huang Yuhua, Xu Yaoting, Zhang Jie, Ma Tonghui, Xu Danfeng, Gao Yi

Abstract excerpt

BACKGROUND: Currently, the clinical strategy for diagnosis of non-muscle invasive bladder cancer (NMIBC) such as cystoscopy and cytology are invasive and/or with limited accuracy. OncoUrine, a urinary assay for mutation and methylation biomarkers, have showed a high accuracy in the detection of upper tract urinary carcinoma (UTUC) patients with hematuria. The aim of this study is to evaluate the performance of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Hematuria

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Methylation

Share to Mutation

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 37726806
DOI: 10.1186/s12916-023-03065-5
PMCID: PMC10510256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.PMID 37726806Read ↗

Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancerSemantic proximity Read ↗

Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and SurveillanceSemantic proximity Read ↗

Uromonitor®: Clinical Validation and Performance Assessment of a Urinary Biomarker for Recurrence Surveillance in Non-Muscle Invasive Bladder Cancer PatientsSemantic proximity Read ↗

Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence.Semantic proximity Read ↗

Roles for epigenetic and other biomarkers in upper tract urothelial carcinoma diagnosis and surveillanceSemantic proximity Read ↗

Urinary DNA Methylation Test for Bladder Cancer DiagnosisSemantic proximity Read ↗

Bladder cancer detection in urine by novel methylation markersSemantic proximity Read ↗

Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancerSemantic proximity Read ↗

Non‐invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort studySemantic proximity Read ↗

DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical TrialSemantic proximity Read ↗

Liquid biopsy based on multi-targeted capture of urinary tumor DNA combined with machine learning to detect urothelial carcinoma: a multicenter prospective study.Semantic proximity Read ↗

A Urine-Based Liquid Biopsy Method for Detection of Upper Tract Urinary CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.